Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program.
Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, Maruzzo M, Giannarelli D, Tortora G, Galli L, Rizzo M, De Giorgi U, Antonuzzo L, Bracarda S, Cartenì G, Atzori F, Tamberi S, Procopio G, Fratino L, Lo Re G, Santoni M, Baldessari C, Astone A, Calabrò F, Brunelli M, Porta C, Rescigno P, Basso U, Fornarini G.
Rebuzzi SE, et al. Among authors: rizzo m.
ESMO Open. 2022 Dec;7(6):100634. doi: 10.1016/j.esmoop.2022.100634. Epub 2022 Dec 6.
ESMO Open. 2022.
PMID: 36493602
Free PMC article.